PURPOSE: Phase II multicenter cooperative group study investigated the efficacy and toxicity of the novel anti-microtubule agent dolastatin-10 in patients with advanced breast cancer. PATIENT AND METHODS: Twenty-one patients with measurable metastatic breast cancer were treated with dolastatin-10 at a dose of 400 mcg/m2 by intravenous bolus once every 3 weeks. Patients must have received a total of 1 or 2 prior chemotherapy regimens and have an Eastern Cooperative Oncology Group performance status of 0-2. Patients received this treatment as either a first (n = 11) or second-line (n = 10) chemotherapy for metastatic disease. Eighteen patients (86%) had received a prior anthracycline. The National Cancer Institute provided the dolastatin-10. RESULTS: One out of 21 patients (5%; 95% CI: 0-24%) achieved a partial remission for a duration of 113 days. Four patients maintained stable disease for a median of 87 days. A total of 58 courses of dolastatin-10 were administered. Patients received a median of two cycles of dolastatin-10. Hematologic toxicity was moderate, with 8 patients developing grade 4 neutropenia, and 5 with grade 3 neutropenia; one grade 3 febrile neutropenia was observed. These episodes of grade 3 and 4 neutropenia were experienced on 36% of the treatment cycles. Non-hematologic toxicity was uncommon. CONCLUSION: While the toxicity profile of dolastatin-10 was acceptable, it had minimal activity in this advanced breast cancer study. We are not pursuing further clinical trials of this agent in the setting of advanced breast cancer.
PURPOSE: Phase II multicenter cooperative group study investigated the efficacy and toxicity of the novel anti-microtubule agent dolastatin-10 in patients with advanced breast cancer. PATIENT AND METHODS: Twenty-one patients with measurable metastatic breast cancer were treated with dolastatin-10 at a dose of 400 mcg/m2 by intravenous bolus once every 3 weeks. Patients must have received a total of 1 or 2 prior chemotherapy regimens and have an Eastern Cooperative Oncology Group performance status of 0-2. Patients received this treatment as either a first (n = 11) or second-line (n = 10) chemotherapy for metastatic disease. Eighteen patients (86%) had received a prior anthracycline. The National Cancer Institute provided the dolastatin-10. RESULTS: One out of 21 patients (5%; 95% CI: 0-24%) achieved a partial remission for a duration of 113 days. Four patients maintained stable disease for a median of 87 days. A total of 58 courses of dolastatin-10 were administered. Patients received a median of two cycles of dolastatin-10. Hematologic toxicity was moderate, with 8 patients developing grade 4 neutropenia, and 5 with grade 3 neutropenia; one grade 3 febrile neutropenia was observed. These episodes of grade 3 and 4 neutropenia were experienced on 36% of the treatment cycles. Non-hematologic toxicity was uncommon. CONCLUSION: While the toxicity profile of dolastatin-10 was acceptable, it had minimal activity in this advanced breast cancer study. We are not pursuing further clinical trials of this agent in the setting of advanced breast cancer.
Authors: Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun Journal: CA Cancer J Clin Date: 2005 Jan-Feb Impact factor: 508.702
Authors: K Margolin; J Longmate; T W Synold; D R Gandara; J Weber; R Gonzalez; M J Johansen; R Newman; T Baratta; J H Doroshow Journal: Invest New Drugs Date: 2001 Impact factor: 3.850
Authors: H C Pitot; E A McElroy; J M Reid; A J Windebank; J A Sloan; C Erlichman; P G Bagniewski; D L Walker; J Rubin; R M Goldberg; A A Adjei; M M Ames Journal: Clin Cancer Res Date: 1999-03 Impact factor: 12.531
Authors: G P Kalemkerian; X Ou; M R Adil; R Rosati; M M Khoulani; S K Madan; G R Pettit Journal: Cancer Chemother Pharmacol Date: 1999 Impact factor: 3.333
Authors: Paula C Jimenez; Diego V Wilke; Paola C Branco; Anelize Bauermeister; Paula Rezende-Teixeira; Susana P Gaudêncio; Leticia V Costa-Lotufo Journal: Br J Pharmacol Date: 2019-12-23 Impact factor: 8.739
Authors: Lih-Ching Hsu; David E Durrant; Ching-Chun Huang; Nai-Wen Chi; Riccardo Baruchello; Riccardo Rondanin; Cinzia Rullo; Paolo Marchetti; Giuseppina Grisolia; Daniele Simoni; Ray M Lee Journal: Invest New Drugs Date: 2011-06-08 Impact factor: 3.850
Authors: Daniel S May; Wei-Lun Chen; Daniel D Lantvit; Xiaoli Zhang; Aleksej Krunic; Joanna E Burdette; Alessandra Eustaquio; Jimmy Orjala Journal: J Nat Prod Date: 2017-03-02 Impact factor: 4.050